A number of studies have proposed the benefits of using Tocilizumab (TCZ), an anti‐interleukin 6 (IL‐6) receptor monoclonal antibody, in critical SCD patients with COVID‐19. This evidence concerns the gene IL6 and Schnyder corneal dystrophy.